Innovate Shares Gain After FDA Approves Kidney-Function Assessment Device

Dow Jones01-21

By Connor Hart

Shares of Innovate rose after the Food and Drug Administration approved the company's device to assess kidney function.

The stock was 43% higher, at $7.30, midday Tuesday, the first day of trading after the company received FDA approval after the bell Friday. Shares have gained 48% so far in 2025, though they are down 28% in the last 52 weeks.

MediBeacon, a medical-technology company under Innovation's portfolio of companies, said its Transdermal GFR system is a first-in-kind product that can assess kidney function in patients with normal or impaired kidney function. It works by measuring the clearance rate of an injected fluorescent agent as it leaves the body.

The system is validated for use in the assessment of glomerular filtration rate, or GFR, which is a measure of how well kidneys filter blood, in patients with stable kidney function at the point of care, the company said. It added that while the system requires an injection, it doesn't require blood draws or urine analysis, as is the case with many current practices.

Innovate said the Transdermal GFR system's approval was based on having met its primary efficacy endpoint.

MediBeacon Chief Executive Steve Hanley, said "the potential applications for the TGFR are numerous, and we look forward to exploring them with clinicians both in the hospital and outpatient settings."

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 21, 2025 12:41 ET (17:41 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2505464204?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-22 01:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505464204","market":"us","top_or_hot":-1,"title":"Innovate Shares Gain After FDA Approves Kidney-Function Assessment Device","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Innovate rose after the Food and Drug Administration approved the company's device to assess kidney function. \n</p>\n<p>\n  The stock was 43% higher, at $7.30, midday Tuesday, the first day of trading after the company received FDA approval after the bell Friday. Shares have gained 48% so far in 2025, though they are down 28% in the last 52 weeks. \n</p>\n<p>\n  MediBeacon, a medical-technology company under Innovation's portfolio of companies, said its Transdermal GFR system is a first-in-kind product that can assess kidney function in patients with normal or impaired kidney function. It works by measuring the clearance rate of an injected fluorescent agent as it leaves the body. \n</p>\n<p>\n  The system is validated for use in the assessment of glomerular filtration rate, or GFR, which is a measure of how well kidneys filter blood, in patients with stable kidney function at the point of care, the company said. It added that while the system requires an injection, it doesn't require blood draws or urine analysis, as is the case with many current practices. \n</p>\n<p>\n  Innovate said the Transdermal GFR system's approval was based on having met its primary efficacy endpoint. \n</p>\n<p>\n  MediBeacon Chief Executive Steve Hanley, said \"the potential applications for the TGFR are numerous, and we look forward to exploring them with clinicians both in the hospital and outpatient settings.\" \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 12:41 ET (17:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovate Shares Gain After FDA Approves Kidney-Function Assessment Device</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovate Shares Gain After FDA Approves Kidney-Function Assessment Device\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-22 01:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Innovate rose after the Food and Drug Administration approved the company's device to assess kidney function. \n</p>\n<p>\n  The stock was 43% higher, at $7.30, midday Tuesday, the first day of trading after the company received FDA approval after the bell Friday. Shares have gained 48% so far in 2025, though they are down 28% in the last 52 weeks. \n</p>\n<p>\n  MediBeacon, a medical-technology company under Innovation's portfolio of companies, said its Transdermal GFR system is a first-in-kind product that can assess kidney function in patients with normal or impaired kidney function. It works by measuring the clearance rate of an injected fluorescent agent as it leaves the body. \n</p>\n<p>\n  The system is validated for use in the assessment of glomerular filtration rate, or GFR, which is a measure of how well kidneys filter blood, in patients with stable kidney function at the point of care, the company said. It added that while the system requires an injection, it doesn't require blood draws or urine analysis, as is the case with many current practices. \n</p>\n<p>\n  Innovate said the Transdermal GFR system's approval was based on having met its primary efficacy endpoint. \n</p>\n<p>\n  MediBeacon Chief Executive Steve Hanley, said \"the potential applications for the TGFR are numerous, and we look forward to exploring them with clinicians both in the hospital and outpatient settings.\" \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 12:41 ET (17:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VATE","symbol_name":"Innovate Corp.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505464204","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505464204","pubTimestamp":1737481260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Innovate rose after the Food and Drug Administration approved the company's device to assess kidney function.The stock was 43% higher, at $7.30, midday Tuesday, the first day of trading after the company received FDA approval after the bell Friday. Shares have gained 48% so far in 2025, though they are down 28% in the last 52 weeks.MediBeacon, a medical-technology company under Innovation's portfolio of companies, said its Transdermal GFR system is a first-in-kind product that can assess kidney function in patients with normal or impaired kidney function. It works by measuring the clearance rate of an injected fluorescent agent as it leaves the body.The system is validated for use in the assessment of glomerular filtration rate, or GFR, which is a measure of how well kidneys filter blood, in patients with stable kidney function at the point of care, the company said. It added that while the system requires an injection, it doesn't require blood draws or urine analysis, as is ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VATE":"Innovate Corp.","BK4129":"建筑与工程"},"translate_title":"FDA批准肾功能评估设备后Innovate股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VATE":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Innovate rose after the Food and Drug Administration approved the company's device to assess kidney function. \n\n\n  The stock was 43% higher, at $7.30, midday Tuesday, the first day of trading after the company received FDA approval after the bell Friday. Shares have gained 48% so far in 2025, though they are down 28% in the last 52 weeks. \n\n\n  MediBeacon, a medical-technology company under Innovation's portfolio of companies, said its Transdermal GFR system is a first-in-kind product that can assess kidney function in patients with normal or impaired kidney function. It works by measuring the clearance rate of an injected fluorescent agent as it leaves the body. \n\n\n  The system is validated for use in the assessment of glomerular filtration rate, or GFR, which is a measure of how well kidneys filter blood, in patients with stable kidney function at the point of care, the company said. It added that while the system requires an injection, it doesn't require blood draws or urine analysis, as is the case with many current practices. \n\n\n  Innovate said the Transdermal GFR system's approval was based on having met its primary efficacy endpoint. \n\n\n  MediBeacon Chief Executive Steve Hanley, said \"the potential applications for the TGFR are numerous, and we look forward to exploring them with clinicians both in the hospital and outpatient settings.\" \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2025 12:41 ET (17:41 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2505464204"}